EGFR and adenocarcinoma: According to the literature, 10–13% of Caucasian patients with adenocarcinoma (which represents the most part of non-squamous NSCLC) presents an EGFR activating mutation, 2–7% rearrangements of ALK and 1–4% BRAF mutations [2,22].